A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs INCB 50465 (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 27 Jul 2017 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019.
- 27 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 29 Sep 2016 Status changed from not yet recruiting to recruiting.